Prema Maria Mertz

Array ( [id] => 16253536 [patent_doc_number] => 20200262910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => TREATMENT OF HEPATOTOXICITY [patent_app_type] => utility [patent_app_number] => 16/748698 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832154 [patent_doc_number] => 11008395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies against IL-7R alpha subunit and uses thereof [patent_app_type] => utility [patent_app_number] => 16/748518 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 48 [patent_no_of_words] => 48735 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17250114 [patent_doc_number] => 11185584 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Anti-IL-23 antibodies, compositions, methods and uses [patent_app_type] => utility [patent_app_number] => 16/745989 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 30737 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18242000 [patent_doc_number] => 20230074311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => COMPOSITION FOR CANCER DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 17/793158 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004965 [patent_doc_number] => 20220363731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => INTERLEUKIN-2 DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/771032 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085539 [patent_doc_number] => 11535657 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases [patent_app_type] => utility [patent_app_number] => 16/729698 [patent_app_country] => US [patent_app_date] => 2019-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 14 [patent_no_of_words] => 15805 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16729698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076287 [patent_doc_number] => 12350322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation [patent_app_type] => utility [patent_app_number] => 17/419163 [patent_app_country] => US [patent_app_date] => 2019-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 32395 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090419 [patent_doc_number] => 20200199196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => MUTANT TUMOR NECROSIS FACTOR RECEPTOR (TNFR) LIGANDS AND METHODS OF MAKING AND USING SAME [patent_app_type] => utility [patent_app_number] => 16/717373 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16717373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952457 [patent_doc_number] => 11478531 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Compositions and methods for inducing a treg phenotype and methods for use for the same [patent_app_type] => utility [patent_app_number] => 16/717340 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 63 [patent_no_of_words] => 9677 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16717340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236677 [patent_doc_number] => 11180549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody [patent_app_type] => utility [patent_app_number] => 16/717594 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 41003 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16717594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178354 [patent_doc_number] => 11155588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use [patent_app_type] => utility [patent_app_number] => 16/715038 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25085 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134821 [patent_doc_number] => 11136367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Multi-level specific targeting of cancer cells [patent_app_type] => utility [patent_app_number] => 16/704645 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13401 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16704645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236676 [patent_doc_number] => 11180548 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Methods of neutralizing IL-8 biological activity [patent_app_type] => utility [patent_app_number] => 16/697310 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 47 [patent_no_of_words] => 119104 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16697310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376360 [patent_doc_number] => 20200325202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => IL-2 MUTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/693741 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029721 [patent_doc_number] => 11091526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => IL-2 muteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/693693 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15493 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17490464 [patent_doc_number] => 11279753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders [patent_app_type] => utility [patent_app_number] => 16/693046 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 21 [patent_no_of_words] => 18000 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060142 [patent_doc_number] => 11104729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Anti-IL-33 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/687257 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 23846 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342195 [patent_doc_number] => 20220008526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/293995 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18329271 [patent_doc_number] => 11634499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Control of trace metals during production of anti-CD38 antibodies [patent_app_type] => utility [patent_app_number] => 16/682551 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 55215 [patent_no_of_claims] => 77 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18128976 [patent_doc_number] => 11555175 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Cell culture methods and media comprising N-acetylcysteine [patent_app_type] => utility [patent_app_number] => 16/679713 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14431 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679713 [rel_patent_id] =>[rel_patent_doc_number] =>)